霍奇金淋巴瘤治疗进展培训课件.ppt
- 【下载声明】
1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
3. 本页资料《霍奇金淋巴瘤治疗进展培训课件.ppt》由用户(晟晟文业)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 霍奇金 淋巴瘤 治疗 进展 培训 课件
- 资源描述:
-
1、霍奇金淋巴瘤治疗进展霍奇金淋巴瘤治疗进展Hodgkins Lymphoma by Era n=2167Overall Survival(y)403020100Cum Survival1.0.8.6.4.20.01960s1970s1980s1990s10 yJoe Connors霍奇金淋巴瘤治疗进展2不同预后组的治疗疗效不同预后组的治疗疗效:Europe and North-America EuropeStage Cure Rates(GSHG and EORTC)早期预后良好组早期预后良好组 CS I,IIA,B no risk factors98%早期预后不良组早期预后不良组 CS I,I
2、IA,B with risk factors93%进展期进展期 CS III IV,Selected CS IIB with ABVD (North America)65-80%(intermediate)霍奇金淋巴瘤治疗进展3霍奇金淋巴瘤治疗进展4Causes of Death among 2733 Patients with Hodgkins Disease (1960-97)Hodgkins Disease38341.2%Secondary Cancers20021.5%MDS111.2%Cardiovascular 14815.9%Pulmonary 414.4%Infection 3
3、53.8%Trauma/Suicide161.7%Other/Unknown9610.3%Total930100.%Stanford,R.Hoppe霍奇金淋巴瘤治疗进展5Did we learn from our mistakesover 40 years?霍奇金淋巴瘤治疗进展6个体化治疗!对于早期患者 如何在保证疗效的情况下尽可能减少副作用?能否进一步减少化疗疗程?减小放疗剂量?晚期患者 如何进一步提高治愈率?霍奇金淋巴瘤治疗进展7霍奇金淋巴瘤治疗进展8预后不良(Unfavorable)早期HLu年龄年龄50岁岁u4个淋巴结区域受侵个淋巴结区域受侵u单独单独ESR50uB症状和症状和ESR3
4、0u纵隔大肿块,或肿块直径大于纵隔大肿块,或肿块直径大于10cmu2个结外部位受累个结外部位受累霍奇金淋巴瘤治疗进展9预后良好(Favorable)早期HLu不符合预后不良组条件的不符合预后不良组条件的其它其它临床临床I/II期期HL霍奇金淋巴瘤治疗进展10 Hodgkin Lymphoma:早期预后不良组 Is less more?寻找高效和低毒间的最佳平衡点霍奇金淋巴瘤治疗进展11CS III without risk factorsABVDABVD30 Gy IFABVDABVDABVDABVDABVDABVDABVDABVDABVDABVD30 Gy IF20 Gy IF20 Gy I
5、F早期预后良好组:GHSG:HD10-Trial 霍奇金淋巴瘤治疗进展12HD10,4th Interim Analysis,August 20061OS(CT-Comparison)5764xABVD561534454323208925762xABVD2.56152246433820097Pts.at RiskOverall Survival months4xABVD2xABVDProbability0.00.10.20.30.40.50.60.70.80.91.0012243648607284OS rates and 95%CI at 5 years*:4xABVD:97%;95%;98%
6、2xABVD:96%;94%;98%霍奇金淋巴瘤治疗进展13HD10,4th Interim Analysis,August 2006Survival curves are Kaplan-Meier estimates.Median observation time is 53 months,N=1109OS(RT-Comparison)55330Gy54551343932520610055620Gy54351145331418680Pts.at RiskOverall Survival months30Gy20GyProbability0.00.10.20.30.40.50.60.70.80
7、.91.0012243648607284OS rates and 95%CI at 5 years:30Gy:97%;95%;98%20Gy:96%;94%;98%霍奇金淋巴瘤治疗进展14HD10结论 2ABVD is non-inferior to 4ABVD 20Gy IF-RT is non-inferior to 30Gy IF-RT 霍奇金淋巴瘤治疗进展151)减少化疗疗程的可能性减少化疗疗程的可能性?2)Do we need bleomycin and dacarbacin in ABVD?霍奇金淋巴瘤治疗进展16霍奇金淋巴瘤治疗进展17413FFTF38826917084413O
8、S408314219114Pts.at RiskTime monthsKaplan-Meier-AnalysenGesamt Survival und FFTFFFTFOSProbability0.00.10.20.30.40.50.60.70.80.91.006121824FFTF at 18 months91%,95%CI 88,94OS at 18 months 100%,95%CI 99,100Overall Survival and FFTF Median observation time:18 months霍奇金淋巴瘤治疗进展18 对于反应良好者化疗是否足够对于反应良好者化疗是否足
9、够?霍奇金淋巴瘤治疗进展19CS I/II without RF*霍奇金淋巴瘤治疗进展20早期患者联合治疗VS 单化疗联合ABVDTotal2673(9 trials)330(3 trials)EFS8099%(84%)89.5,86,87%OS8899%(94%)90,96,96霍奇金淋巴瘤治疗进展21早期预后良好患者2ABVD+20 Gy IF-RT是标准治疗!是标准治疗!单化疗、减药化疗+放疗尚待随机研究结果霍奇金淋巴瘤治疗进展22霍奇金淋巴瘤治疗进展23Hodgkin LymphomaIntermediate StagesFact:Combined chemo-and radiothe
10、rapy islargely considered as standard:4 ABVD+30 Gy IF-RTResult:90%tumorfree survival after 5 years 93%overall survival after 5 years霍奇金淋巴瘤治疗进展241)Better Results with intensified chemotherapy?霍奇金淋巴瘤治疗进展251450 pats recruited since 2003霍奇金淋巴瘤治疗进展26447FFTF427361233111449OS444397290150Pts.at RiskTime mon
11、thsFFTFOSProbability0.00.10.20.30.40.50.60.70.80.91.006121824At 18 monthsFFTF:93%95%CI:90;96 OS:100%95%CI:99;100 GHSG 04/2006霍奇金淋巴瘤治疗进展27EORTC Trials:H10+H11Standard Arm:3 ABVD+30Gy IF-RTNeg 1 ABVD no RTPos 2 BEACOPP esc+RTEarly Favorable:H102 ABVD PETNeg +2 ABVD no RTEarly Unfavorable:H112 ABVD PET
12、Experim.ArmExperim.ArmStandard Arm 4 ABVD+30Gy IF-RT霍奇金淋巴瘤治疗进展28Hodgkin LymphomaEarly and Intermediate Stages Summary The GHSG experience Standard outside clinical trials:Early favorable:2ABVD+20 Gy IF-RT Early unfavorable:4 ABVD+20-30 Gy IF-RT (intermediate)霍奇金淋巴瘤治疗进展29霍奇金淋巴瘤治疗进展30Hodgkin Lymphoma
13、Advanced Stages Current PracticeIntensive Chemotherapy CR:no RT PR:30 Gy IF-RT Chemotherapy:IF-RT6-8 ABVD (45%RT)Or 6-8 BEACOPP (15%RT)霍奇金淋巴瘤治疗进展31Advanced Stages:-ABVD-the Gold Standard?No!It is not!At least not for all risk groups!霍奇金淋巴瘤治疗进展32Long-Term Follow-upAdvanced HL:only stages IIB-LMM,III,
14、IV!Failure-free survivalOverall survivalYears after study entryCanellos et al.NEJM,2002霍奇金淋巴瘤治疗进展33Fourth Generation Regimens:are they superior to ABVD?1.Stanford V 2.ClVP/EVA 3.MEC(Gobbi:10 drug regimen!)(JCO 2005)4.BEACOPP霍奇金淋巴瘤治疗进展34Gobbi PG,et al.J Clin Oncol.2005;23(36):9198-9207.Epub 2005 Sept
展开阅读全文